{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:14:51Z","timestamp":1776492891143,"version":"3.51.2"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.cca.2015.12.015","type":"journal-article","created":{"date-parts":[[2015,12,15]],"date-time":"2015-12-15T19:47:44Z","timestamp":1450208864000},"page":"147-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Clinical laboratory application of a reporter-gene assay for measurement of functional activity and neutralizing antibody response to infliximab"],"prefix":"10.1016","volume":"453","author":[{"given":"Igor Y.","family":"Pavlov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Carper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eszter","family":"L\u00e1z\u00e1r-Moln\u00e1r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio C.","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.cca.2015.12.015_bb0005","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/ajg.2011.58","article-title":"An evidence-based systematic review on medical therapies for inflammatory bowel disease","volume":"106","author":"Talley","year":"2011","journal-title":"Am. J. Gastroenterol."},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2015.12.015_bb0010","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1478-6354-13-S1-S2","article-title":"Infliximab: 12years of experience","volume":"13","author":"Smolen","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cca.2015.12.015_bb0015","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cca.2015.12.015_bb0020","article-title":"Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice","volume":"S39-50","author":"Vande Casteele","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.cca.2015.12.015_bb0025","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1080\/00365520802699278","article-title":"Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies","volume":"44","author":"Bendtzen","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.cca.2015.12.015_bb0030","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2165\/00003495-200464160-00004","article-title":"Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease","volume":"64","author":"Han","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.cca.2015.12.015_bb0035","first-page":"241","article-title":"Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases","volume":"29","author":"Thomas","year":"2015","journal-title":"Syst. Rev. Metaanal. Biodrugs"},{"key":"10.1016\/j.cca.2015.12.015_bb0040","first-page":"201","article-title":"Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists","volume":"15","author":"Bendtzen","year":"2013","journal-title":"Discov. Med."},{"key":"10.1016\/j.cca.2015.12.015_bb0045","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/ajg.2014.110","article-title":"Toward a personalized medicine approach to the management of inflammatory bowel disease","volume":"109","author":"Mosli","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cca.2015.12.015_bb0050","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cca.2015.12.015_bb0055","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cca.2015.12.015_bb0060","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","article-title":"Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial","volume":"63","author":"Steenholdt","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.cca.2015.12.015_bb0065","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1007\/s10620-015-3581-4","article-title":"Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn\u2019s disease patients failing infliximab","volume":"60","author":"Steenholdt","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.cca.2015.12.015_bb0070","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.cgh.2012.12.035","article-title":"A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab","volume":"11","author":"Velayos","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cca.2015.12.015_bb0075","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/ibd.21919","article-title":"Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies","volume":"18","author":"Kopylov","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.cca.2015.12.015_bb0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jim.2012.06.002","article-title":"Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum","volume":"382","author":"Wang","year":"2012","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.cca.2015.12.015_bb0085","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jim.2011.08.022","article-title":"Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNF\u03b1 antagonists","volume":"373","author":"Lallemand","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.cca.2015.12.015_bb0090","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1097\/MIB.0b013e31829936c2","article-title":"Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"19","author":"Costa","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.cca.2015.12.015_bb0095","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jpba.2011.03.038","article-title":"Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics","volume":"55","author":"Gupta","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.cca.2015.12.015_bb0100","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/2050640613502962","article-title":"CD25 and TNF receptor II reflect early primary response to infliximab therapy in patients with ulcerative colitis","volume":"1","author":"Magnusson","year":"2013","journal-title":"U. Eur. Gastroenterol. J."},{"key":"10.1016\/j.cca.2015.12.015_bb0105","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/FTD.0000000000000074","article-title":"Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization","volume":"36","author":"Gils","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cca.2015.12.015_bb0110","unstructured":"Kirshner S. Guidance for Industry Assay Development for Immunogenicity Testing of Therapeutic Proteins. (http:\/\/wwwfdagov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM192750pdf 2009)."},{"key":"10.1016\/j.cca.2015.12.015_bb0115","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/FTD.0b013e31828d23c3","article-title":"Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease","volume":"35","author":"Steenholdt","year":"2013","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cca.2015.12.015_bb0120","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/apt.12030","article-title":"Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays","volume":"36","author":"Vande Casteele","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.cca.2015.12.015_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2014.106","article-title":"Thomsen Oe, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn\u2019s disease: post hoc analysis of a randomized controlled trial","author":"Steenholdt","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cca.2015.12.015_bb0130","article-title":"Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn\u2019s disease","volume":"238-245","author":"Steenholdt","year":"2015","journal-title":"J. Crohns Colitis"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000989811530084X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000989811530084X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T14:56:47Z","timestamp":1599922607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000989811530084X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":26,"alternative-id":["S000989811530084X"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2015.12.015","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical laboratory application of a reporter-gene assay for measurement of functional activity and neutralizing antibody response to infliximab","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2015.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}